Farallon Capital Management’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Farallon Capital Management’s Portfolio ARNA Stock Details ARNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-522,000	Closed	-$48.5M	–	350
2021 Q4	$48.5M	Sell	522,000 -134,548	-20%	-$8.86M	0.24%	65
2021 Q3	$39.1M	Sell	656,548 -193,452	-23%	-$11.4M	0.18%	82
2021 Q2	$58M	Hold	850,000	–	–	0.24%	66
2021 Q1	$59M	Buy	850,000 +100,000	+13%	+$7.69M	0.29%	64
2020 Q4	$57.6M	Buy	750,000 +120,114	+19%	+$9M	0.35%	60
2020 Q3	$47.1M	Sell	629,886 -270,114	-30%	-$18M	0.33%	64
2020 Q2	$56.7M	Buy	+900,000	New	+$49.5M	0.45%	54

Farallon Capital Management's ARNA Position: Q1 2022 in Review

Farallon Capital Management sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 522,000 shares — an estimated $48.5M sold.

Farallon Capital Management first reported a position in ARNA in Q2 2020 and held it in 7 quarters. The position peaked at $59M in Q1 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

Farallon Capital Management reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
Farallon Capital Management sold 522,000 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $48.5M.
Farallon Capital Management first reported a position in Arena Pharmaceuticals Inc in Q2 2020 and held it in 7 quarters.
Farallon Capital Management's Arena Pharmaceuticals Inc position peaked at $59M in Q1 2021.
1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on Farallon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.